Sponsor study identifier
interventional
369
1 country
15
Study Start
November 7, 2019
Actual (reported)Primary Completion
February 17, 2020
Actual (reported)Study Completion
February 17, 2020
Actual (reported)The objective of this study is to evaluate the safety and effectiveness of lubricating and rewetting drop (Test) compared to OPTI-FREE® Replenish® Rewetting Drops (Control) when used by habitual contact lens wearers to bilaterally lubricate and rewet soft (hydrophilic) contact lenses including silicone hydrogel contact lenses and gas permeable (silicone acrylate and fluoro silicone acrylate) contact lenses.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 17, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 7, 2019
Actual (reported)November 20, 2019
Actual (reported)November 25, 2019
Actual (reported)February 17, 2020
Actual (reported)February 17, 2020
Actual (reported)July 10, 2024
Actual (reported)Overall Comfort Averaged Over All Follow-up Visits
Overall comfort will be assessed for each eye on a scale from 0 to 100, with 100 denoting the most favorable response. For each eye, mean overall comfort over all follow-up visits will be computed as the average of the non-missing values overall scheduled follow-up visits.
1 month
Dryness Averaged Over All Follow-up Visits
Dryness will be assessed for each eye on a scale from 0 to 100, with 100 denoting the most favorable response. For each eye, mean dryness over all follow-up visits will be computed as the average of the non-missing values over all scheduled follow-up visits.
1 month
Proportion of Eyes With Slit Lamp Findings Greater Than Grade 2 at Any Follow-up Visit
At each follow-up visit, graded slit lamp findings will be assessed for each eye using Grades 0 through 4. Using only the non-missing observations from all visits without imputation, each eye will be classified with respect to findings greater than grade 2 at any visit (Absent, Present).
1 month
Preservative Free Lubricating and Rewetting Drops for use during contact lens wear
Replenish Rewetting Drops
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Bausch Site 108
San Francisco, California, 94112, United States
Bausch Site 111
Torrance, California, 90503, United States
Bausch Site 106
Sarasota, Florida, 34237, United States
Bausch Site 104
Decatur, Georgia, 30035, United States
Bausch Site 110
Bloomington, Kansas, 61704, United States
Bausch Site 112
Leavenworth, Kansas, 66048, United States
Bausch Site 107
Portland, Maine, 04101, United States
369 participants (actual enrollment reported by the registry).
First Submitted
November 20, 2019
First Posted
November 25, 2019
Study Start
November 7, 2019
Actual (reported)Vistakon Investigational Multi-purpose Contact Lens Care Solution.
Contact the study team to confirm eligibility.
Bausch Site 109
Edina, Minnesota, 55436, United States
Bausch Site 102
Jamestown, New York, 14701, United States
Bausch Site 113
Vestal, New York, 13850, United States
Bausch Site 101
Miamisburg, Ohio, 45342, United States
Bausch Site 105
West Chester, Ohio, 45069, United States
Bausch Site 114
Grants Pass, Oregon, 97526, United States
Bausch Site 115
Brentwood, Tennessee, 37027, United States
Bausch Site 103
Nashville, Tennessee, 37205, United States
Primary Completion
February 17, 2020
Actual (reported)Study Completion
February 17, 2020
Actual (reported)Last Updated
July 10, 2024
Results First Posted
July 10, 2024
Record last verified: 2023-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: